Search for 'an,phr: 6' with limit(s): 'au:Pulido Ortega, Federico'

Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.

By Pulido Ortega, Federico. HIV medicine, 2015 . 16(6):370-4. , Formato Vancouver: Martínez E, Ribera E, Clotet B, Estrada V, Sanz J, Berenguer J et al. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio. HIV Med. 2015 Jul;16(6):370-4.

Place Hold on Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

By Pulido Ortega, Federico. HIV clinical trials, 2015 . 16(1):43-8. , Formato Vancouver: Pedrol E, Caro Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P et al. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study. HIV Clin Trials. 2015 Jan-Feb;16(1):43-8.

Place Hold on Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

¿Cómo está afectando la aplicación del nuevo marco legal sanitario a la asistencia de los inmigrantes infectados por el VIH en situación irregular en España?.

By Pulido Ortega, Federico. Enfermedades infecciosas y microbiología clínica, 2015 . 33(7):437-45. , Formato Vancouver: Pérez Molina JA, Pulido F; Comité de expertos del Grupo para el Estudio del Sida (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). ¿Cómo está afectando la aplicación del nuevo marco legal sanitario a la asistencia de los inmigrantes infectados por el VIH en situación irregular en España?. Enferm Infecc Microbiol Clin. 2015 Aug-Sep;33(7):437-45.

Place Hold on ¿Cómo está afectando la aplicación del nuevo marco legal sanitario a la asistencia de los inmigrantes infectados por el VIH en situación irregular en España?.

Genetic barrier to resistance for dolutegravir.

By Pulido Ortega, Federico | Delgado Vázquez, Rafael. AIDS reviews, 2015 . 17(1):56-64. , Formato Vancouver: Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015 Jan-Mar;17(1):56-64.

Place Hold on Genetic barrier to resistance for dolutegravir.

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

By Pulido Ortega, Federico. Enfermedades infecciosas y microbiología clínica, 2015 . 33(8):544-56. , Formato Vancouver: Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR et al; Expert Panel of GESIDA and the National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56.

Place Hold on Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

By Pulido Ortega, Federico. Enfermedades infecciosas y microbiología clínica, 2015 . 33(3):156-65. , Formato Vancouver: Blasco AJ, Llibre JM, Berenguer J, González García J, Knobel H, Lozano F et al; GESIDA ART Cost-efficacy Study Group. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enferm Infecc Microbiol Clin. 2015 Mar;33(3):156-65.

Place Hold on Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

By Pulido Ortega, Federico | Rubio García, Rafael . Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2015 . 60(6):950-8. , Formato Vancouver: Berenguer J, Zamora FX, Aldámiz Echevarría T, Von Wichmann MA, Crespo M, López Aldeguer J et al; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2015 Mar 15;60(6):950-8.

Place Hold on Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

By Pulido Ortega, Federico. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014 . 18(6):700-8. , Formato Vancouver: Monge S, Díez M, Pulido F, Iribarren JA, Campins AA, Arazo P et al; Spanish AIDS Research Network Cohort (CoRIS). Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8.

Place Hold on Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes.

Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients.

By Pulido Ortega, Federico | Rubio García, Rafael . AIDS (London, England), 2014 . 28(9):1279-87. , Formato Vancouver: Macías J, González J, Tural C, Ortega González E, Pulido F, Rubio R et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS. 2014 Jun 1;28(9):1279-87.

Place Hold on Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients.

Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral.

By Lagarde Sebastián, María de | Bisbal Pardo, Otilia | Pulido Ortega, Federico. Enfermedades infecciosas y microbiología clínica, 2014 . 32 Suppl 3:12-7. , Formato Van couver: Sebastián Mde L, Pardo OB, Ortega FP. Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral. Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:12-7.

Place Hold on Lopinavir/ritonavir en nuevas estrategias de simplificación del tratamiento antirretroviral.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

By Pulido Ortega, Federico | Rubio García, Rafael . Enfermedades infecciosas y microbiología clínica, 2014 . 32(7):447-58. , Formato Vancouver: Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR et al; Expert Panel of GeSIDA and the National Aids Plan. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):447-58.

Place Hold on Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade.

By Delgado Vázquez, Rafael | Pulido Ortega, Federico | Rubio García, Rafael . Archives of virology, 2014 . 159(5):1079-87. , Formato Vancouver: Yebra G, Delgado R, Pulido F, Rubio R, Galán JC, Moreno S et al. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade. Arch Virol. 2014 May;159(5):1079-87.

Place Hold on Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade.

Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

By Lagarde Sebastián, María de | Pulido Ortega, Federico | Rubio García, Rafael . PloS one, 2013 . 8(7):e69493. , Formato Vancouver: Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One. 2013 Jul 25;8(7):e69493.

Place Hold on Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

By Pulido Ortega, Federico. Lancet, 2013 . 381(9868):735-43. , Formato Vancouver: Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C et al. SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735-43.

Place Hold on Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

By Pulido Ortega, Federico | Rubio García, Rafael . HIV medicine, 2013

Place Hold on Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study.

By Pulido Ortega, Federico. Aids Research and Human Retroviruses, 2013 . 29(2):256-65. , Formato Vancouver: Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013 Feb;29(2):256-65.

Place Hold on Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study.

Recomendaciones de GESIDA/Secretaria del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizacion enero de 2013).

By Pulido Ortega, Federico. Enfermedades infecciosas y microbiología clínica, 2013 . 31(10):672-84. , Formato Vancouver: Rivero A, Pulido F, Caylá J, Iribarren JA, Miró JM, Moreno S et al. Grupo de Estudio de Sida (GESIDA); Secretaría del Plan Nacional sobre el Sida. [The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida). Recomendaciones de GESIDA/Secretaria del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizacion enero de 2013). Enferm Infecc Microbiol Clin. 2013 Dec;31(10):672-84.

Place Hold on Recomendaciones de GESIDA/Secretaria del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualizacion enero de 2013).

Enfermedades de transmisión sexual

By Pulido Ortega, Federico | Acedo Gutiérrez, Mª Soledad. Madrid: MSD, 1994 . p. 355-363 , Formato Vancouver: Pulido Ortega F, Acedo Gutiérrez MS. Enfermedades de transmisión sexual. En: Carnevali Ruiz D, Medina Iglesias P, Pastor Valverde C, Sánchez Manzano, Satué Bartolomé JA, editores. Manual de diagnóstico y terapéutica médica. Madrid: MSD; 1994. p. 355-63

Place Hold on Enfermedades de transmisión sexual

Tuberculosis

By Salmerón Béliz, Octavio J. | Pulido Ortega, Federico. Madrid: MSD, 1994 . p. 407-415 , Formato Vancouver: Salmerón Béliz OJ, Pulido Ortega F. Tuberculosis. En: Carnevali Ruiz D, Medina Iglesias P, Pastor Valverde C, Sánchez Manzano, Satué Bartolomé JA, editores. Manual de diagnóstico y terapéutica médica. Madrid: MSD; 1994. p. 407-15

Place Hold on Tuberculosis

Infección por el virus de la inmunodeficiencia humana

By Pulido Ortega, Federico | Castilla Castellanos, Virgilio | Satué Bartolomé, José Ángel. Madrid: MSD, 1994 . p. 417-431 , Formato Vancouver: Pulido Ortega F, Castilla Castellanos V, Satué Bartolomé JA. Infección por el virus de la inmunodeficiencia humana. En: Carnevali Ruiz D, Medina Iglesias P, Pastor Valverde C, Sánchez Manzano, Satué Bartolomé JA, editores. Manual de diagnóstico y terapéutica médica. Madrid: MSD; 1994. p. 417-31.

Place Hold on Infección por el virus de la inmunodeficiencia humana

Infecciones en el paciente inmunocomprometido

By Pulido Ortega, Federico | Salmerón Béliz, Octavio J.. Madrid: MSD, 1994 . p. 319-325 , Formato Vancouver: Pulido Ortega F, Salmerón Béliz OJ. Infecciones en el paciente inmunocomprometido. En: Carnevali Ruiz D, Medina Iglesias P, Pastor Valverde C, Sánchez Manzano, Satué Bartolomé JA, editores. Manual de diagnóstico y terapéutica médica. Madrid: MSD; 1994. p. 319-25.

Place Hold on Infecciones en el paciente inmunocomprometido

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

By Pulido Ortega, Federico. AIDS (London, England) , 2013 . 27(11):1771-8. , Formato Vancouver: Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F et al. SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013 Jul 17;27(11):1771-8.

Place Hold on Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.

By Pulido Ortega, Federico. The Journal of antimicrobial chemotherapy, 2013 . 68(6):1373-81. , Formato Vancouver: Bernardino JI, Pulido F, Martínez E, Arrizabalaga J, Domingo P, Portilla J et al. GESIDA-6008-KRETA Study Group. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013 Jun;68(6):1373-81.

Place Hold on Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

By Pulido Ortega, Federico. Journal of hepatology, 2013 . 58(6):1104-12. , Formato Vancouver: Berenguer J, Álvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J et al. GESIDA HIV/HCV Cohort Study Group. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013 Jun;58(6):1104-12.

Place Hold on Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.

By Pulido Ortega, Federico. International Journal of Std & Aids, 2013 . 24(8):679-81. , Formato Vancouver: Arribas J, Pulido F, Hill A, Delft Yv, Moecklinghoff C. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. Int J STD AIDS. 2013 Aug;24(8):679-81.

Place Hold on Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial.

Update on Clinical and Methodological Recommendations for Genotypic Determination of HIV tropism to Guide the Usage of CCR5 Antagonists.

By Delgado Vázquez, Rafael | Pulido Ortega, Federico. Aids Reviews, 2012 . 14(3):208-17. , Formato Vancouver: Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R et al. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Rev. 2012 Jul-Sep;14(3):208-17.

Place Hold on Update on Clinical and Methodological Recommendations for Genotypic Determination of HIV tropism to Guide the Usage of CCR5 Antagonists.

Should We Look for Strongyloides Stercoralis in Foreign-Born HIV-Infected Persons?.

By Fiorante, Silvana | Llenas García, Jara | Maseda Fernández, Diego | Matarranz del Amo, Mariano | Pulido Ortega, Federico | Rodríguez, Violeta | Rubio García, Rafael | Salto, Efren. Journal of Immigrant and Minority Health, 2012 . 15(4):796-802. , Formato Vancouver: Llenas-García J, Fiorante S, Salto E, Maseda D, Rodríguez V, Matarranz M, Hernando A, Rubio R, Pulido F. Should we look for Strongyloides stercoralis in foreign-born HIV-infected persons? J Immigr Minor Health. 2013 Aug;15(4):796-802.

Place Hold on Should We Look for Strongyloides Stercoralis in Foreign-Born HIV-Infected Persons?.

Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos.

By Fiorante, Silvana | Llenas García, Jara | Maseda Fernández, Diego | Matarranz del Amo, Mariano | Pulido Ortega, Federico | Costa Pérez-Herrero, José Ramón | Rubio García, Rafael . Enfermedades Infecciosas y Microbiologia Clínica, 2012 . 30(8):441-51. , Formato Vancouver: Llenas-García J, Rubio R, Hernando A, Fiorante S, Maseda D, Matarranz M, et al. Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos. Enferm Infecc Microbiol Clin. 2012 Oct;30(8):441-51.

Place Hold on Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos.

Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?.

By Arrazola Martínez, María Pilar | Llenas García, Jara | Pulido Ortega, Federico | Rubio García, Rafael . AIDS Care, 2013 . 25(8):980-9. , Formato Vancouver: Llenas-García J, Rubio R, Hernando A, Arrazola P, Pulido F. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization? AIDS Care. 2013 Aug;25(8):980-9.

Place Hold on Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?.

Modificación de la carga viral y CD4 en enfermos con Viremia indetectable a los que se les reintroduce la terapia antirretroviral tras una suspensión inferior a 3 meses

By Campillos Paéz, María Teresa | Rubio García, Rafael | Pulido Ortega, Federico. . p. 181. , Formato Vancouver: Campillos Páez MT, Rubio García R, Pulido Ortega F. Modificación de la carga viral y CD4 en enfermos con Viremia indetectable a los que se les reintroduce la terapia antirretroviral tras una suspensión inferior a 3 meses. En: 5as Jornadas del Área 11 de Salud: "Los profesionales de la salud al servicio de los pacientes": Resúmenes de Ponencias y Comunicaciones: Días 1, 2 y 3 de Diciembre de 1998, Hospital Universitario 12 de Octubre. Madrid: Gerencia del Área 11 de Atención Primaria, Gerencia del Área 11 de Atención Especializada, 1998. p. 181.

Place Hold on Modificación de la carga viral y CD4 en enfermos con Viremia indetectable a los que se les reintroduce la terapia antirretroviral tras una suspensión inferior a 3 meses

Lack of the Detection of XMRV or Polytropic MLV-Related Sequences in Blood Cells From HIV-1–Infected Patients in Spain.

By Delgado Vázquez, Rafael | Fiorante, Silvana | Luczkowiak, Joanna | Martínez Prats, Lorena | Rodríguez Otero, Joaquín | Pulido Ortega, Federico | Rubio García, Rafael | Olalla Sierra, Julián. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2012 . 59(2):101-4. , Formato Vancouver: Luczkowiak J, Martínez-Prats L, Sierra O, Fiorante S, Rubio R, Pulido F, et al. Lack of the detection of XMRV or polytropic MLV-related sequences in blood cells from HIV-1-infected patients in Spain. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):101-4.

Place Hold on Lack of the Detection of XMRV or Polytropic MLV-Related Sequences in Blood Cells From HIV-1–Infected Patients in Spain.

Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos.

By Costa Pérez-Herrero, José Ramón | Fiorante, Silvana | Hernando Jerez, Asunción | Llenas García, Jara | Maseda Fernández, Diego | Matarranz del Amo, Mariano | Pulido Ortega, Federico | Rubio García, Rafael . Enfermedades Infecciosas y Microbiología Clínica, 2012 . 30(8):441-51. , Formato Vancouver: Llenas-García J, Rubio R, Hernando A, Fiorante S, Maseda D, Matarranz M, et al. Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos. Enferm Infecc Microbiol Clin. 2012 Oct;30(8):441-51.

Place Hold on Características clínico-epidemiológicas de los pacientes inmigrantes con infección por el VIH: estudio de 371 casos.

No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.

By Pulido Ortega, Federico. AIDS Research and Human Retroviruses, 2012 . ;28(10):1167-9. , Formato Vancouver: Pulido F, Arribas J, Hill A, Moecklinghoff C. No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1167-9.

Place Hold on No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.

Definition of advanced age in HIV infection: looking for an age cut-off

By Pulido Ortega, Federico | Rubio García, Rafael . AIDS Research and Human Retroviruses, 2012 . 28(9):1000-1006. , Formato Vancouver: Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, et al. Definition of advanced age in HIV infection: looking for an age cut-off. AIDS Res Hum Retroviruses. 2012;28(9):1000-6.

Place Hold on Definition of advanced age in HIV infection: looking for an age cut-off

Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem.

By Fiorante, Silvana | Llenas García, Jara | Maseda Fernández, Diego | Matarranz del Amo, Mariano | Pulido Ortega, Federico | Rubio García, Rafael . European Journal of Clinical Microbiology & Infectious Diseases, 2012 . 31(8):1991-7. , Formato Vancouver: Llenas-García J, Hernando A, Fiorante S, Maseda D, Matarranz M, Salto E, et al. Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem. Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1991-7.

Place Hold on Chagas disease screening among HIV-positive Latin American immigrants: an emerging problem.

Estrategias de inducción-mantenimiento de tratamiento antirretroviral

By Pulido Ortega, Federico. Barcelona: Permanyer, 2005 . p. 63-84. , Formato Vancouver: Paño JR, Arribas JR, Pulido F. Estrategias de inducción-mantenimiento de tratamiento antirretroviral. En: González-García J, Moreno Guillén S, Rubio García R, editores. Infección por VIH 2004. Barcelona: Permanyer; 2005. p. 63-84.

Place Hold on Estrategias de inducción-mantenimiento de tratamiento antirretroviral

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy

By Pulido Ortega, Federico. Antiviral Therapy, 2011 . 16(1):59-65. , Formato Vancouver: Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther. 2011;16(1):59-65.

Place Hold on Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results

By Pulido Ortega, Federico. HIV Clinical Trials, 2011 . 12(5):255-267. , Formato Vancouver: Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials. 2011;12(5):255-67.

Place Hold on Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the PROGRESS study, 48-week results

Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy

By Delgado Vázquez, Rafael | Pulido Ortega, Federico. Antiviral Therapy, 2011 . 16(5):725-732. , Formato Vancouver: McKinnon JE, Delgado R, Pulido F, Shao W, Arribas JR, Mellors JW. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther. 2011;16(5):725-32.

Place Hold on Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy

Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial

By Pulido Ortega, Federico. AIDS, 2011 . 25(3):393-394. , Formato Vancouver: Paton NI, Meynard JL, Pulido F, Arenas Pinto A, Girard PM, Arribas J. Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. AIDS. 2011;25(3):393-4.

Place Hold on Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial

Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient

By Delgado Vázquez, Rafael | Fiorante, Silvana | Llenas García, Jara | Luczkowiak, Joanna | Martínez Prats, Lorena | Pulido Ortega, Federico. AIDS Research and Human Retroviruses, 2011 . 27(1):41-45. , Formato Vancouver: Martínez-Prats L, Luczkowiak J, Gutiérrez F, Zurita S, Fiorante S, Llenas-García J, et al. Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient. AIDS Res Hum Retroviruses. 2011;27(1):41-5.

Place Hold on Sustained profile of transmitted drug resistance mutations for more than 10 years in an HIV type 1-infected patient

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis

By Pulido Ortega, Federico. PLoS One, 2011 . 6(7):e22003. , Formato Vancouver: Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One. 2011;6(7):e22003.

Place Hold on Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis